Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Yale University
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)